Table 1.
Relationships between CRE and VRE perirectal swab results and demographic data.
| CRE (Carbapenem-Resistant Enterobacterales) | VRE (Vancomycin-Resistant Enterococci) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Positive n (%) |
Negative n (%) |
Total n (%) |
p < 0.05 | Positive n (%) |
Negative n (%) |
Total n (%) |
p < 0.05 | ||
| Sex | 125 (100) | 0.436 | 125 (100) | 0.240 | |||||
| Female | 12 (35.3) | 41 (45.1) | 53 (42.4) | 1 (16.7) | 52 (43.7) | 53 (42.4) | |||
| Male | 22 (64.7) | 50 (54.9) | 72 (57.6) | 5 (83.3) | 67 (56.3) | 72 (57.6) | |||
| Gestational age | 0.932 | 0.408 | |||||||
| <32 weeks | 5 (14.7) | 19 (20.9) | 24 (19.2) | 1 (16.7) | 23 (19.3) | 24 (19.2) | |||
| 32–36 weeks | 15 (44.1) | 17 (18.7) | 32 (25.6) | 2 (33.3) | 30 (25.2) | 32 (25.6) | |||
| 37 weeks and over | 14 (41.2) | 55 (60.4) | 69 (55.2) | 3 (50) | 66 (55.5) | 69 (55.2) | |||
| * Birth weight (g) (min-max) | 2732.5 (2200–3100) | 2900 (2240–3400) | - | 0.313 | 2900 (2200–3270) | 2780 (2200–3300) | - | 0.849 | |
| * Hospitalization weight (g) | 2745 (2220–3110) | 2910 (2100–3370) | - | 0.504 | 2730 (2010–3110) | 2850 (2200–3300) | - | 0.742 | |
| * Hospitalization age—days (min-max) | 14 (7–21) | 9 (4–18) | - | 0.110 | 7.5 (5–14) | 11 (4–20) | - | 0.431 | |
| Name of Healthcare Center | 125 (100) | 0.777 | 125 (100) | 1.000 | |||||
| City of Mersin | 28 (82.4) | 71 (78) | 99 (79.2) | 5 (83.3) | 94 (79) | 99 (79.2) | |||
| Outside the city | 6 (17.6) | 20 (22) | 26 (20.8) | 1 (16.7) | 25 (21) | 26 (20.8) | |||
| Mode of delivery | 125 (100) | 0.552 | 125 (100) | 0.176 | |||||
| Normal delivery | 9 (26.5) | 31 (34.1) | 40 (32.0) | 0 (0) | 40 (33.6) | 40 (32.0) | |||
| Cesarean | 25 (73.5) | 60 (65.9) | 85 (68.0) | 6 (100) | 79 (66.4) | 85 (68) | |||
| External center antibiotherapy | 125 (100) | 0.165 | 125 (100) | 0.867 | |||||
| No antibiotic treatment | 9 (26.5) | 18 (19.8) | 27 (21.6) |
1 (16.7) | 26 (21.8) | 27 (21.6) | |||
| Empirical (ampicillin- gentamicin) | 13 (38.2) | 49 (53.8) | 62 (49.6) | 3 (50) | 59 (49.6) | 62 (49.6) | |||
| # Broad-spectrum antibiotic | 12 (35.3) | 24 (26.4) | 36 (28.8) | 2 (33.3) | 34 (28.6) | 36 (28.8) | |||
| Externalcenter antibiotherapy duration | 125 (100) | 0.764 | 125 (100) | 0.634 | |||||
| 0 days | 9 (26.5) | 17 (18.7) | 26 (20.8) | 9 (25) | 18 (20.2) | 27 (21.6) | |||
| 1–10 days | 19 (55.9) | 68 (74.7) | 87 (69.6) | 21 (58.3) | 65 (73.0) | 86 (68.8) | |||
| >10 days | 6 (17.6) | 6 (6.6) | 12 (9.6) | 6 (16.7) | 6 (6.7) | 12 (9.6) | |||
* Median (minimum and maximum) values are given instead of “n” and “%”, # Carbapenem + Vancomycin ± Amikacin ± Antifungal therapy, Abbreviations: CRE, carbapenem-resistant Entrobacterales; VRE, vancomycin-resistant Enterococci.